Single Blood Test Achieves High Accuracy for Multicancer Detection

A breakthrough low-cost blood test, MethylScan, is demonstrating remarkable accuracy in detecting multiple cancers and diseases simultaneously. Developed using cell-free DNA (cfDNA) methylome sequencing, the assay enriches and analyzes hypermethylated cfDNA fragments.

In trials, the test achieved a 0.938 AUROC for multicancer detection across liver, lung, ovarian, and stomach cancers, with 63.3% sensitivity at 98.0% specificity. For early-stage cancers, the AUROC was 0.916. The assay also showed strong performance in liver cancer surveillance, with a 0.927 AUROC and 79.6% sensitivity at 90.4% specificity.

These findings suggest a more accessible and scalable approach to multicancer detection, potentially revolutionizing screening and enabling earlier interventions for various diseases.